| Date | Product | Disease | Phase | Company | Therapeutic area |
|---|---|---|---|---|---|
| 2012-09-27 | AMA0076 | glaucoma |
2a | Amakem (Belgium) | Ophtalmological diseases |
| 2012-09-26 | ColoAd1 | metastatic solid tumors | 1-2 | PsiOxus Therapeutics (UK) | Cancer - Oncology |
| 2012-09-26 | olokizumab | rheumatoid arthritis | 2b | UCB (Belgium) | Autoimmune diseases – Inflammatory diseases - Rheumatic diseases |
| 2012-09-24 | NVC-422 (N,N-dichloro-2,2-dimethyltaurine) | impetigo |
2b | Galderma (Switzerland) Novabay Pharmaceuticals (USA) | Infectious diseases |
| 2012-09-22 | AG013 | prevention of oral mucositis | 1 | ActoGeniX (Belgium) | Cancer - Oncology |
| 2012-09-20 | simeprevir (TMC435) and TMC647055 | C hepatitis | 2a | Medivir (Sweden) Janssen (J&J - USA) | Infectious diseases |
| 2012-09-20 | MOR103 | rheumatoid arthritis |
1-2a | Morphosys (Germany) | Autoimmune diseases – Inflammatory diseases - Rheumatic diseases |
| 2012-09-19 | NiCord® (expanded cell graft derived from an entire unit of umbilical cord blood enriched with stem cells) | acute lymphoblastic leukemia (ALL), acute myelogenous leukemia (AML) myelodysplastic syndrome (MDS) non-Hodgkin's lymphoma, Hodgkin's disease | 1-2 | Gamida Cell (Israel) | Cancer - Oncology |
| 2012-09-18 | ALX-0171 | Respiratory Syncytial Virus (RSV) infections |
1 | Ablynx (Belgium) | Respiratory diseases - Infectious diseases |
| 2012-09-18 | APR-246 | hematological malignancies, prostate carcinoma | 1-2 | Aprea (Sweden) | Cancer - Oncology |
| 2012-09-18 | Vaccine Enhancement Patch in combination with GSK\'s H5N1 pandemic Influenza antigen | pandemic influenza | 1 | Intercell (Austria) | Infectious diseases |
| 2012-09-17 | JX594/TG6006 (Pexa-Vec) | hepatocellular carcinoma | 2 | Jennerex (USA) Transgene (France) | Cancer - Oncology |
| 2012-09-17 | VAS203 | traumatic brain injury | 2a | Vasopharm (Germany) | Traumatology - CNS diseases |
| 2012-09-14 | cell culture based pandemic flu vaccine co-developed with GlaxoSmithKline (GSK) and using Vivalis’ EB66® cell line | influenza |
3 | Kaketsuken (Japan) GSK (UK) | Infectious diseases |
| 2012-09-13 | ZP2929 | diabetes | 1 | Zealand Pharma (Denmark) | Metabolic diseases |
| 2012-09-13 | Flunisyn® (pan-strain influenza-A T-cell vaccine) | influenza | 1 | Immune Targeting Systems (UK) | Infectious diseases |
| 2012-09-12 | Vacc-4x | HIV-Aids | 2 | Bionor Pharma (Norway) | Infectious diseases |
| 2012-09-12 | rifamycin SV MMX® | travellers’ diarrhoea | 3 | Cosmo Pharmaceuticals (Italy) Santarus (USA) | Infectious diseases |
| 2012-09-11 | tetravalent dengue vaccine candidate | dengue fever |
2b | Sanofi Pasteur (France) | Infectious diseases |
| 2012-09-11 | long-acting blood factors VIIa, VIII and IX | hemophilia A | preclinical data | Pro Bono Bio (UK) | Hematologic diseases - Genetic diseases - Rare diseases |
